CN101044152A - 组合RNAi治疗的方法和组合物 - Google Patents

组合RNAi治疗的方法和组合物 Download PDF

Info

Publication number
CN101044152A
CN101044152A CNA2005800119560A CN200580011956A CN101044152A CN 101044152 A CN101044152 A CN 101044152A CN A2005800119560 A CNA2005800119560 A CN A2005800119560A CN 200580011956 A CN200580011956 A CN 200580011956A CN 101044152 A CN101044152 A CN 101044152A
Authority
CN
China
Prior art keywords
sirna
composition
vegf
experimenter
target
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA2005800119560A
Other languages
English (en)
Chinese (zh)
Inventor
B·－J·李
P·Y·卢
M·C·伍德尔
F·Y·谢
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Silence Therapeutics PLC
Original Assignee
Intradigm Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Intradigm Corp filed Critical Intradigm Corp
Publication of CN101044152A publication Critical patent/CN101044152A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/111—General methods applicable to biologically active non-coding nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1131—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/17—Immunomodulatory nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/31—Combination therapy

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Virology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
CNA2005800119560A 2004-02-05 2005-02-07 组合RNAi治疗的方法和组合物 Pending CN101044152A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US54177604P 2004-02-05 2004-02-05
US60/541,776 2004-02-05

Publications (1)

Publication Number Publication Date
CN101044152A true CN101044152A (zh) 2007-09-26

Family

ID=34860217

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA2005800119560A Pending CN101044152A (zh) 2004-02-05 2005-02-07 组合RNAi治疗的方法和组合物

Country Status (5)

Country Link
EP (1) EP1713819A4 (de)
CN (1) CN101044152A (de)
AU (1) AU2005213485A1 (de)
CA (1) CA2555531A1 (de)
WO (1) WO2005076999A2 (de)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111620939A (zh) * 2019-10-25 2020-09-04 南京市妇幼保健院 一种用于治疗或辅助治疗卵巢癌的多肽zyx36-58
CN114196785A (zh) * 2020-09-18 2022-03-18 北京大学人民医院 异基因造血干细胞移植后巨细胞病毒对巨核细胞易感性的生物标记物及其应用
CN114452393A (zh) * 2022-02-22 2022-05-10 南方科技大学 Pinch-1蛋白作为靶点在制备治疗肺纤维化的药物中的应用
WO2023174356A1 (zh) * 2022-03-17 2023-09-21 圣诺生物医药技术(苏州)有限公司 一种核酸干扰药物组合物及用于治疗结直肠癌、胃癌和前列腺癌的药物

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8491914B2 (en) * 2004-02-13 2013-07-23 Ibc Pharmaceuticals, Inc. Dock-and-lock (DNL) complexes for delivery of interference RNA
EP1817416A2 (de) * 2004-11-05 2007-08-15 Intradigm Corporation Zusammensetzungen zur behandlung viraler atemwegsinfektionen und deren verwendung
KR101169668B1 (ko) 2005-01-07 2012-08-07 알닐람 파마슈티칼스 인코포레이티드 ＲＳＶ의 ＲＮＡｉ 조절 및 이를 위한 약제학적 조성물
JP2008537752A (ja) * 2005-04-12 2008-09-25 イントラディグム コーポレイション がんおよび他の新血管形成疾患を処置するためのＲＮＡｉ治療用の組成物および方法
WO2007025254A2 (en) * 2005-08-26 2007-03-01 Henry Ford Health System Investigation and treatment of cancer using a g-protien coupled eicosnoid receptor
EP1970078A4 (de) * 2006-01-11 2010-11-17 Kyowa Hakko Kirin Co Ltd Zusammensetzung zur hemmung eines target-gens in einem augapfel und heilmittel für eine augapfel-erkrankung
TW200836762A (en) * 2006-11-27 2008-09-16 Enzon Pharmaceuticals Inc Polymeric short interfering RNA conjugates
CN101583715A (zh) * 2006-12-21 2009-11-18 因特拉迪格姆公司 用于治疗癌症的抑制性多核苷酸组合物和方法
WO2008118013A2 (en) 2007-03-23 2008-10-02 To-Bbb Holding B.V. Targeted intracellular delivery of antiviral agents
CA2701128A1 (en) 2007-10-01 2009-04-09 Isis Pharmaceuticals, Inc. Antisense modulation of fibroblast growth factor receptor 4 expression
US8735567B2 (en) 2007-11-06 2014-05-27 Patrick Y. Lu Multi-targeted RNAi therapeutics for scarless wound healing of skin
WO2009151539A1 (en) 2008-05-24 2009-12-17 Sirnaomics, Inc. COMPOSITIONS AND METHODS USING siRNA MOLECULES FOR TREATMENT OF GLIOMAS
WO2010078517A2 (en) 2008-12-31 2010-07-08 Sirnaomics, Inc. Compositions and methods using sirna molecules and sirna cocktails for the treatment of breast cancer
US9642873B2 (en) 2010-05-04 2017-05-09 Sirnaomics, Inc. Combinations of TGFβ and COX-2 inhibitors and methods for their therapeutic application
WO2012016139A2 (en) 2010-07-29 2012-02-02 Sirnaomics, Inc. Sirna compositions and methods for treatment of hpv and other infections
EP2721156B1 (de) 2011-06-16 2016-12-21 Ionis Pharmaceuticals, Inc. Antisense-modulierung der expression des fibroblastenwachstumsfaktor-rezeptors 4
CN103007291B (zh) * 2011-09-26 2015-04-29 苏州圣诺生物医药技术有限公司 双靶标/多靶标小核酸治疗眼部疾病的组合物及应用
CN102399820B (zh) * 2011-09-27 2013-06-12 天津佰思普生物科技有限公司 针对hpv16 e7基因的小干扰rna及其应用
US9868952B2 (en) 2012-07-08 2018-01-16 Sirnaomics, Inc. Compositions and methods for “resistance-proof” SiRNA therapeutics for influenza
AU2016226414B2 (en) 2015-03-02 2021-09-09 180 Therapeutics Lp Method of treating a localized fibrotic disorder using an IL-33 antagonist
EP4035659A1 (de) 2016-11-29 2022-08-03 PureTech LYT, Inc. Exosome zur ausgabe von therapeutischen wirkstoffen
CN106771252A (zh) * 2017-01-13 2017-05-31 福建医科大学 Amacr蛋白在制备肝癌术后预后评估试剂盒中的应用及试剂盒
EP4093511A4 (de) * 2020-01-23 2023-10-18 Sirnaomics, Inc. Zusammensetzung und verfahren von rnai-prophylaktika und -therapeutika zur behandlung schwerer akuter atemwegsinfektionen, verursacht durch das neue coronavirus 2019 (2019-ncov)

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003243541A1 (en) * 2002-06-12 2003-12-31 Ambion, Inc. Methods and compositions relating to labeled rna molecules that reduce gene expression
CN1922330A (zh) * 2003-04-25 2007-02-28 因特拉迪格姆公司 用于抗SARS冠状病毒治疗的RNAi物质

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111620939A (zh) * 2019-10-25 2020-09-04 南京市妇幼保健院 一种用于治疗或辅助治疗卵巢癌的多肽zyx36-58
CN111620939B (zh) * 2019-10-25 2021-01-01 南京市妇幼保健院 一种用于治疗或辅助治疗卵巢癌的多肽zyx36-58
CN114196785A (zh) * 2020-09-18 2022-03-18 北京大学人民医院 异基因造血干细胞移植后巨细胞病毒对巨核细胞易感性的生物标记物及其应用
CN114452393A (zh) * 2022-02-22 2022-05-10 南方科技大学 Pinch-1蛋白作为靶点在制备治疗肺纤维化的药物中的应用
WO2023174356A1 (zh) * 2022-03-17 2023-09-21 圣诺生物医药技术(苏州)有限公司 一种核酸干扰药物组合物及用于治疗结直肠癌、胃癌和前列腺癌的药物

Also Published As

Publication number Publication date
WO2005076999A2 (en) 2005-08-25
AU2005213485A1 (en) 2005-08-25
EP1713819A2 (de) 2006-10-25
EP1713819A4 (de) 2007-11-14
CA2555531A1 (en) 2005-08-25
WO2005076999A3 (en) 2006-07-06

Similar Documents

Publication Publication Date Title
CN101044152A (zh) 组合RNAi治疗的方法和组合物
CN1189562C (zh) 针对核糖核苷酸还原酶r1和r2组分的抗肿瘤反义序列
CN1836042A (zh) 用于基因沉默的hbv和hcv保守序列
Thi et al. ARB-1740, a RNA interference therapeutic for chronic hepatitis B infection
CN1918292A (zh) 用于调节bcl－2的寡聚化合物
CN1177378A (zh) 稳定的外部指导序列
CN1934255A (zh) 用于治疗眼新血管疾病的组合治疗
CN1268980A (zh) 用于鉴定选择性抑制丙型肝炎病毒复制的试剂的新筛选方法
Weinzierl et al. Effective chemokine secretion by dendritic cells and expansion of cross-presenting CD4−/CD8+ dendritic cells define a protective phenotype in the mouse model of coxsackievirus myocarditis
CN1203632A (zh) P16表达构建物及其在癌治疗中的应用
CN105903036A (zh) miR-130a反义核酸及其衍生物在Hippo-YAP信号通路抑制剂中的应用
US20220042020A1 (en) Pharmaceutical composition that inhibits production of hepatitis b virus protein and screening method
CN1784242A (zh) 通过小核糖核酸病毒直接介导的溶瘤作用治疗受试者恶性肿瘤的方法
Bock et al. Subcellular mislocalization of mutant hepatitis BX proteins contributes to modulation of STAT/SOCS signaling in hepatocellular carcinoma
CN1718194A (zh) 治疗肌肉萎缩的寡核苷酸药物
CN1302107C (zh) 与硫氧还蛋白或硫氧还蛋白还原酶基因互补的寡核苷酸序列以及将其用于调节细胞生长的方法
CN1701077A (zh) 反义寡核苷酸用于抑制Akt－1表达的用途
CN1793359A (zh) HBV特异性干涉靶位点基因及其siRNA和其在抗HBV感染中的应用
CN105899238B (zh) 通过调节微RNAmiR-130a、miR-130b、miR-204或miR-1236治疗肝炎病毒感染
Bhosle et al. Evaluation of cellular determinants required for in vitro xenotropic murine leukemia virus-related virus entry into human prostate cancer and noncancerous cells
CN1948483A (zh) 抑制人RabJ基因表达的siRNA及其应用
TW200808361A (en) RNAi-mediated inhibition of histamine receptor H1-related conditions
CN101054591A (zh) 靶向激活慢性粒细胞白血病蛋白激酶pkr的寡核苷酸及其应用
KR20170005627A (ko) Parp 및 탄키라제 동시 저해제에 대한 감수성 결정 방법
CN1809583A (zh) 抑制hif－1表达的反义寡核苷酸

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Open date: 20070926